Reata Pharmaceuticals Inc (NASDAQ:RETA) insider Keith Wayne Ward sold 4,750 shares of the stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $59.48, for a total value of $282,530.00. Following the completion of the sale, the insider now directly owns 4,750 shares in the company, valued at $282,530. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Keith Wayne Ward also recently made the following trade(s):
- On Tuesday, October 23rd, Keith Wayne Ward sold 14,250 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $57.08, for a total value of $813,390.00.
Shares of NASDAQ:RETA opened at $62.10 on Friday. Reata Pharmaceuticals Inc has a 1 year low of $19.31 and a 1 year high of $99.50.
Large investors have recently made changes to their positions in the company. Point72 Asset Management L.P. bought a new position in shares of Reata Pharmaceuticals during the second quarter valued at $6,962,000. Wallace Capital Management Inc. bought a new position in shares of Reata Pharmaceuticals during the second quarter valued at $271,000. MetLife Investment Advisors LLC lifted its holdings in shares of Reata Pharmaceuticals by 72.7% during the second quarter. MetLife Investment Advisors LLC now owns 7,732 shares of the company’s stock valued at $270,000 after purchasing an additional 3,255 shares in the last quarter. First Manhattan Co. bought a new position in shares of Reata Pharmaceuticals during the second quarter valued at $807,000. Finally, Sio Capital Management LLC bought a new position in Reata Pharmaceuticals in the second quarter valued at about $1,533,000. 40.73% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have recently commented on RETA. BidaskClub raised Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. Zacks Investment Research raised Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $100.00 price target on shares of Reata Pharmaceuticals in a report on Monday, October 1st. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $133.00 price target on shares of Reata Pharmaceuticals in a report on Wednesday, September 26th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $139.00 price target (up from $116.00) on shares of Reata Pharmaceuticals in a report on Tuesday, September 25th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Reata Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $100.33.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Recommended Story: Fundamental Analysis
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.